In the present study, we found that CXCL9, CXCL10, and CCL25 could also serve as biomarkers for AIP/IgG4-RD inasmuch as serum concentrations of these factors were markedly higher in patients AIP/IgG4-RD than in those with CP or healthy controls. This evidence concerns the gene CXCL9 and immunoglobulin G4-related sclerosing disease.